TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01310777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Study: NCT01452438

Intervention type: BIOLOGICAL
Intervention: MenACWY-CRM
Description: MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
Study: NCT03188393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo stereotactic biopsy
Study: NCT02877966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amixea
Description: Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01380015

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercially spearmint tea
Description: Commercially available, non-selectively bred spearmint tea.
Study: NCT02203396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit ATG, Cyclosporine, Levamisole
Description: rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
Study: NCT01713920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEVIKAR
Study: NCT03448796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO
Description: Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physiotherapeutic program
Description: Group that receives only supervised physiotherapy as treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physiotherapeutic program
Description: Group that receives only supervised physiotherapy as treatment.
Study: NCT02485873

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians

Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: As prescribed by treating physicians
Study: NCT03502005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bictegravir/emtricitabine/tenofovir alafenamide
Description: Discontinue ATRIPLA® and initiate BIKTARVY®
Study: NCT04100083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 50 MG
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 100mg
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 200 mg
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Study: NCT03255122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CALM
Description: Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed I-CALM
Description: Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
Study: NCT00406250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: 1.25 mg in 0.05 cc of bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: 1.25 mg of bevacizumab intravitreally injected in a steril field
Study: NCT03635281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvers
Description: Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental PEEP
Description: In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
Study: NCT03536208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
Study: NCT02491684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a Nebuliser solution 48 μg/mL
Description: Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for once daily inhalation for 14 days
Study: NCT03184688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
Study: NCT01826019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
Study: NCT04495023

Intervention type: PROCEDURE
Intervention: Left elective colectomy
Description: Open or laparoscopic left elective colectomy with colo-rectal anastomosis

Intervention type: PROCEDURE
Intervention: Left elective colectomy
Description: Open or laparoscopic left elective colectomy with colo-rectal anastomosis
Study: NCT01350947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.
Study: NCT01188343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each; Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each, Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each, subcutaneous (SC)
Study: NCT01380015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Rosmarinic Acid Spearmint Tea
Description: The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
Study: NCT03635593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD+THC
Description: Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
Study: NCT01003678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.
Study: NCT04433702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle
Description: The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle
Description: The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device
Study: NCT00665912

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively
Description: GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-lobectomy wound care
Description: Standard post-lobectomy wound care
Study: NCT01970722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IP or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IP or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04502030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01861314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT03292926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will help treat pain and sensation after ACL repair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will help treat pain and sensation after ACL repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound will guide anesthesiologist in performing the different nerve blocks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound will guide anesthesiologist in performing the different nerve blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be used to prolong block duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be used to prolong block duration
Study: NCT05683028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
Study: NCT03234595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebraca wafer
Description: Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
Study: NCT04552301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Asthma Education
Description: The manualized 10-session program of asthma self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Asthma Education
Description: A 10-session program of similar time
Study: NCT04762095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness stress reduction program
Description: mindfulness stress reduction program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness stress reduction program
Description: mindfulness stress reduction program
Study: NCT04263623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing no active drug.
Study: NCT02105740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
Study: NCT04423666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking using a wireless pedometer
Description: See arm/group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking using a wireless pedometer
Description: See arm/group
Study: NCT04046367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
Study: NCT01010828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision technique
Description: Tri-Vector Approach retains the majority of 3 vectors of quadriceps.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision technique
Description: Mini Mid-Vastus Approach